NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
Clinical Trials
13 trialsNCT03970447 2026-04-08
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT04503694 2026-03-27
REGINA
Jules Bordet Institute
Phase 2 Active not recruiting
NCT06275919 2026-03-27
MIRAGE
Istituto Oncologico Veneto IRCCS
Phase 2 Recruiting
NCT06902246 2026-03-27
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07495579 2026-03-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT05395741 2026-03-25
Regbone
Institute of Mother and Child, Warsaw, Poland
Phase 1/2 Active not recruiting
NCT06246643 2026-03-19
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Bayer
Phase 2 Active not recruiting
NCT07483684 2026-03-19
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed